



**Houston Marriott  
at the Texas  
Medical Center**  
6580 Fannin Street  
Houston, TX 77030  
Phone: (832) 796-0080

Jointly provided by:



# 7<sup>th</sup> Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

Saturday, June 23, 2018

7:00 AM - 4:00 PM

**Program Chair  
Fredrick Hagemester, MD**

Professor of Medicine,  
Department of Lymphoma/Myeloma  
The University of Texas MD Anderson Cancer Center,  
Houston, TX

## Educational Grants

Takeda Oncology  
Bayer HealthCare Pharmaceuticals Inc.  
Celgene Corporation  
Novartis Pharmaceuticals Corporation

For online registration and more information visit:  
[www.cancernetus.com](http://www.cancernetus.com)

## REGISTRATION FORM

## 7<sup>th</sup> Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

First Name \_\_\_\_\_ Middle Initial \_\_\_\_\_ Last Name \_\_\_\_\_

Physician  Pa-C  NP  PhD  Pharmacist  Industry  Nurse  Other

Mailing Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email \_\_\_\_\_

Specialty \_\_\_\_\_

Fax registration to: 443-267-0016

Mail registration to:  
860 Hebron Pkwy, Suite 1104  
Lewisville, TX 75057

Check box to receive information  
about Live and Webcast programs.  
You can unsubscribe at any time.

### Registration Fee (Registration fee includes buffet breakfast, lunch and syllabus book.)

	Early Registration Fee - Up to 5/31/18	Discounted Registration Fee - 6/1/18 - 6/15/18	Regular Registration Fee - 6/16/18 - 6/23/18
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Nurses, Nurse Practitioners, Physician Assistants	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Pharmacists, Fellows	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Industry †	\$350.00	\$400.00	\$450.00

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

**No refund; substitution is allowed.**

Payment may be made:  MC  Visa  Discover  Check

Credit Card Number \_\_\_\_\_ Expiration Date \_\_\_\_\_

Name and address (as given on the monthly credit card statement) \_\_\_\_\_

Pharmacist e-profile NABP#: \_\_\_\_\_ Pharmacist DOB (MMDD): \_\_\_\_\_

Signature \_\_\_\_\_

Register online at [www.cancernetus.com](http://www.cancernetus.com)  
Please make checks payable to **CancerNet**, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: [brianw@cancernetus.com](mailto:brianw@cancernetus.com)

## Faculty

### **Jorge Cortes, MD**

Professor and Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center Houston, TX

### **Nathan Fowler, MD**

Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Fredrick B. Hagemeister, MD**

Professor of Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Nitin Jain, MD**

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Elisabet E. Manasanch, MD**

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Sattva S. Neelapu, MD**

Professor of Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Robert Orlowski, MD, PhD**

Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Farhad Ravandi, MD**

Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center Houston, TX

### **William G. Wierda, MD**

Professor of Medicine, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

## 7<sup>th</sup> Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

**Saturday, June 23, 2018**

**Houston Marriott at the Texas Medical Center**

6580 Fannin Street, Houston, TX 77030

Phone: (713) 796-0080

### Statement of Need / Program Overview

This symposium is intended to improve care of patients with Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

### Target Audience

This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

### Learning Objectives

- Describe the biology and mechanism of action of CAR-T cells in hematological malignancies
- Evaluate the therapeutic efficacy and safety of axicabtagene ciloleucel, tisagenlecleucel and B-cell maturation antigen (BCMA) in patients with selected hematological malignancies
- Assess the efficacy and safety of PD-1 and PD-L1 blockade in combination with brentuximab vedotin and autologous stem cell and allogenic stem cell transplantation in patients with Hodgkin's lymphoma HL
- Cite the newer treatment options for follicular lymphoma
- Identify the newer treatment options for mantle cell lymphoma
- Apply the novel treatment options for chronic lymphocytic lymphoma
- Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active multiple myeloma (MM)
- Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
- Evaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia
- Evaluate how compound genotypes are related to novel therapeutic option based outcomes in patients with acute myeloid leukemia
- Identify response assessment and management of tyrosine kinase inhibitor resistance in the treatment of chronic myeloid leukemia

# Agenda 7<sup>th</sup> Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

7:00 AM	Pre-registration (Buffet Breakfast)	
8:25 AM	Welcome and Introductions	<i>Fredrick Hagemeister, MD</i>
<b>GENERAL TOPIC</b>		
8:30 AM	Pretest - Case Report Vignettes	<i>Sattva S. Neelapu, MD / Fredrick Hagemeister, MD</i>
8:40 AM	Overview of Biology and Mechanism of Action of CAR T-cells and Potential Therapeutic Efficacy in Selected Hematological Malignancies	<i>Sattva S. Neelapu, MD</i>
<b>B-CELL LYMPHOMAS (HL, FL, MCL, CLL)</b>		
9:05 AM	Overview of Immunotherapy and Combination Therapy Options for Hodgkin's Lymphoma	<i>Fredrick Hagemeister, MD</i>
9:30 AM	Posttest - Case Report Vignettes	<i>Sattva S. Neelapu, MD / Fredrick Hagemeister, MD</i>
9:40 AM	Pretest - Case Report Vignettes	<i>Fredrick Hagemeister, MD / Nathan Fowler, MD</i>
9:50 AM	Overview of Treatment Options for Diffuse Large Cell Lymphoma (DLCL)	<i>Fredrick Hagemeister, MD</i>
10:15 AM	<b>BREAK</b>	
10:30 AM	Overview of Treatment Options for Follicular Lymphoma (FL)	<i>Nathan Fowler, MD</i>
10:55 AM	Posttest - Case Report Vignettes	<i>Fredrick Hagemeister, MD / Nathan Fowler, MD</i>
11:05 AM	Pretest - Case Report Vignettes	<i>TBD / William Wierda, MD</i>
11:15 AM	Overview of Treatment Options for Mantle Cell Lymphoma (MCL)	<i>TBD</i>
11:40 AM	Overview of Treatment Options for Chronic Lymphocytic Leukemia (CLL)	<i>William Wierda, MD</i>
12:05 PM	Posttest - Case Report Vignettes	<i>TBD / William Wierda, MD</i>
12:15 PM	<b>LUNCH</b>	
<b>MULTIPLE MYELOMA</b>		
1:00 PM	Pretest - Case Report Vignettes	<i>Elisabet Manasanch, MD / Robert Orlowski, MD, PhD</i>
1:10 PM	An Overview on Systemic Therapy for Patients with Newly Diagnosed Active Multiple Myeloma (MM)	<i>Elisabet Manasanch, MD</i>
1:35 PM	Outline the Selection, Sequencing and/or Combination of Novel Therapies for Patients with Relapsed/refractory MM	<i>Robert Orlowski, MD, PhD</i>
2:00 PM	Posttest - Case Report Vignettes	<i>Elisabet Manasanch, MD / Robert Orlowski, MD, PhD</i>
<b>LEUKEMIA (ALL, AML AND CML)</b>		
2:10 PM	Pretest - Case Report Vignettes	<i>Nitin Jain, MD / Farhad Ravandi, MD / Jorge Cortes, MD</i>
2:20 PM	Novel Therapies for adolescents and young adults (AYA), Philadelphia-positive and Philadelphia-negative Relapsed/Refractory Patients with Acute Lymphoblastic Leukemia	<i>Nitin Jain, MD</i>
2:45 PM	<b>BREAK</b>	
3:00 PM	How Compound Genotypes are Related to Novel Therapy Based Outcomes in Patients with Acute Myeloid Leukemia?	<i>Farhad Ravandi, MD</i>
3:25 PM	Response Assessment and Management of Tyrosine Kinase Inhibitors Resistance in the Management of Patients with Chronic Myeloid Leukemia	<i>Jorge Cortes, MD</i>
3:50 PM	Posttest - Case Report Vignettes	<i>Nitin Jain, MD / Farhad Ravandi, MD / Jorge Cortes, MD</i>
4:00 PM	Closing Remarks and Adjourn	<i>Fredrick Hagemeister, MD</i>

## Physicians / Nurses / Pharmacists



JOINT ACCREDITATION  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Credit Designation Statement - Amedco LLC designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™ for physicians, 6 contact hours for nurses and 6 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.**

**Participants may reserve guest rooms by calling (713) 796-0080**



860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057  
Tel: (972) 459-5222 • Fax: (443) 267-0016  
www.cancernetus.com